Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

May 15, 2012 - PRLog -- the industry analysis specialist, has released its new report, “Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019”. The report is an essential source of information and analysis on the global neuroendocrine carcinoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019. The high growth is primarily attributed to the advent of approved drugs, Sutent (sunitinib) and Afinitor (everolimus), in the major markets. The expected launch of promising drugs in the forecast period will drive the market. The promising drugs to be launched include: Avastin (bevacizumab) and Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) for Gastrointestinal (GI) carcinoid and pancreatic Neuroendocrine Tumors (NETs), pasireotide (SOM 230), and Somatuline (lanreotide acetate) Autogel/Depot for GI carcinoids NETs. These factors will accelerate the growth of the neuroendocrine carcinoma therapeutics market.

Scope

- Annualized data on the seven key neuroendocrine carcinoma markets (the US, France, Germany, Italy, Spain, the UK and Japan) revenue data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends in the market. Pipeline candidates fall under the following mechanisms of action: Somatostatin analogues and Vascular Endothelial Growth Factor (VEGF) inhibitors, insulin-like growth factor-1 receptor (IGFR-1) inhibitors, tyrosine kinase inhibitor (TKI) and Smoothened (Smo) inhibitor.
- Analysis of the current and future competition in the global neuroendocrine carcinoma market. Key market players covered are Novartis AG, Roche, the Eli Lilly & Company, Callisto Pharmaceuticals, Molecular Insight pharmaceuticals, Advanced Accelerator Applications S.A, Roche, Ipsen and Amgen Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, and unmet needs and their implications for the neuroendocrine carcinoma therapeutics market.
- Analysis of key recent licensing and partnership agreements in the neuroendocrine carcinoma market.

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global neuroendocrine carcinoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global neuroendocrine carcinoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What is the next big thing in the global neuroendocrine carcinoma market landscape? Identify, understand and capitalize.

Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action"


for further information visit http://www.reportreserve.com/report/neuroendocrine-carcin...